Top Clicks This Month

2,3,4-TRIFLUOROBENZAMIDE - CAS 207919-09-3

Quick Inquiry

Name:
* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Category
Main Product
Product Name
2,3,4-TRIFLUOROBENZAMIDE
Catalog Number
207919-09-3
Synonyms
2,3,4-TRIFLUOROBENZAMIDE;Trifluorobenzamide1;2,3,4-Trifluorobenzamide 97%;2,3,4-Trifluorobenzamide97%
CAS Number
207919-09-3
Molecular Weight
175.11
Molecular Formula
C7H4F3NO
COA
Inquire
MSDS
Inquire
Canonical SMILES
C1=CC(=C(C(=C1C(=O)N)F)F)F
InChI
InChI=1S/C7H4F3NO/c8-4-2-1-3(7(11)12)5(9)6(4)10/h1-2H,(H2,11,12)
InChIKey
XGOGYOBKQVLGAY-UHFFFAOYSA-N
Structure
CAS 207919-09-3 2,3,4-TRIFLUOROBENZAMIDE
Specification
Purity
95%
Boiling Point
166ºC at 760 mmHg
Melting Point
127-129ºC
Density
1.45g/cm3
Reference Reading
1.Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study.
Beesley VL1, Wockner LF2, O'Rourke P2, Janda M3, Goldstein D4,5, Gooden H6, Merrett ND7,8, O'Connell DL9, Rowlands IJ10, Wyld DK11,12, Neale RE2. Support Care Cancer. 2016 Apr 16. [Epub ahead of print]
PURPOSE: This study aims to determine if the supportive care needs of people with pancreatic cancer change over time and identify the factors associated with current and future unmet needs.
2.Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Koh K1, Ogawa C2,3, Okamoto Y4, Kudo K5,6, Inagaki J7, Morimoto T8, Mizukami H9, Ecstein-Fraisse E9, Kikuta A10. Int J Hematol. 2016 Apr 16. [Epub ahead of print]
A phase 1 study was conducted to evaluate the safety, pharmacokinetics (PK), efficacy and pharmacogenetic characteristics of clofarabine in seven Japanese pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Patients in Cohort 1 received clofarabine 30 mg/m2/day for 5 days, followed by 52 mg/m2/day for 5 days in subsequent cycles. Cohort 2 patients were consistently treated with 52 mg/m2/day for 5 days. No more than six cycles were performed. Every patient had at least one ≥Grade 3 adverse event (AE). AEs (≥Grade 3) related to clofarabine were anaemia, neutropenia, febrile neutropenia, thrombocytopenia, alanine aminotransferase increased, aspartate aminotransferase increased, haemoglobin decreased, and platelet (PLT) count decreased. C max and AUC of clofarabine increased in a dose-dependent fashion, but its elimination half-life (T 1/2) did not appear to be dependent on dose or duration of treatment. Clofarabine at 52 mg/m2/day shows similarly tolerable safety and PK profiles compared to those in previous studies.
3.Targeted Gene Expression in Zebrafish Exposed to Chlorpyrifos-Oxon Confirms Phenotype-Specific Mechanisms Leading to Adverse Outcomes.
Garcia-Reyero N1,2, Escalon L3, Prats E4, Faria M5,6, Soares AM5, Raldúa D6. Bull Environ Contam Toxicol. 2016 Apr 16. [Epub ahead of print]
Zebrafish models for mild, moderate, and severe acute organophosphorus poisoning were previously developed by exposing zebrafish larvae to chlopyrifos-oxon. The phenotype of these models was characterized at several levels of biological organization. Oxidative stress and mitochondrial dysfunction were found to be involved in the development of the more severe phenotype. Here we used targeted gene expression to understand the dose-responsiveness of those two pathways and their involvement on generating the different zebrafish models. As the severe phenotype is irreversible after only 3 h of exposure, we also analyzed the response of the oxidative stress pathway at 3 and 24 h. Some of the genes related to oxidative stress were already differentially expressed at 3 h. There was an increase in differentially expressed genes related to both oxidative stress and mitochondrial function from the more mild to the more severe phenotype, suggesting the involvement of these mechanisms in increasing phenotype severity.
4.Involuntary psychiatric holds - the structure of admissions on the example of Institute of Psychiatry and Neurology in Warsaw.
Markiewicz I1, Heitzman J1, Gardyńska-Ziemba E2. Psychiatr Pol. 2016;50(1):7-18. doi: 10.12740/PP/33336.
OBJECTIVES: The aim of the study was to analyse the structure of involuntary psychiatric holds in Institute of Psychiatry and Neurology in Warsaw, throughout the year. Our research interests included socio-demographic profiles of the patients, time of admissions (time of a day/night/ season), type of diagnoses at admission and suicide attempts preceding the admission. We also analysed the normative aspect of involuntary admissions, i.e. which Articles of the Polish Mental Health Act constituted the basis for these patients admission, and if the choice of articles was justifiable by a diagnosis of the mental disorder.
2005 - BOC Sciences | All rights reserved
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE